Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 26, No. 3, 2010
Issue release date: August 2010
Section title: Original Paper
Cell Physiol Biochem 2010;26:355–362
(DOI:10.1159/000320559)

Effect of Anandamide in Plasmodium Berghei-infected Mice

Bobbala D. · Alesutan I. · Föller M. · Huber S.M.1 · Lang F.1
Department of Physiology and1Department of Radiation Oncology, University of Tübingen*contributed equally and thus share first authorship
email Corresponding Author

Prof. Dr. Florian Lang

Physiologisches Institut, der Universität Tübingen

Gmelinstr. 5, D-72076 Tübingen (Germany)

Tel. +49 7071 29 72194, Fax +49 7071 29 5618

E-Mail florian.lang@uni-tuebingen.de

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Eryptosis, the suicidal death of erythrocytes, is characterized by exposure of phosphatidylserine at the erythrocyte surface and cell shrinkage. Triggers of eryptosis include anandamide. Enhanced eryptosis of infected human erythrocytes is expected to delay the development of parasitaemia during infection with Plasmodium, the parasite causing malaria. The present experiments aimed to test, whether anandamide influences eryptosis, parasite growth and/or host survival during in vitro or in vivo infection with Plasmodia. Human erythrocytes were infected in vitro with P. falciparum, and mice in vivo with P. berghei. Parasitemia was determined with Syto16. Phosphatidylserine-exposing erythrocytes were identified by analysing annexin V-binding in FACS analysis. In vitro infection of human erythrocytes was followed by a significant increase in annexin V-binding, an effect slightly enhanced by anandamide (≧ 50 µM), which significantly reduced intraerythrocytic DNA/RNA content and in vitro parasitaemia. In vivo administration of anandamide (5 mg/kg b.w. subcutaneously) blunted the parasitaemia (from 36.9% to 24.2% of circulating erythrocytes 21 days after infection) and significantly enhanced the survival of P. berghei-infected mice (from 0% to 67% 26 days after infection). The percentage of phosphatidylserine-exposing erythrocytes was significantly increased in anandamide-treated infected mice compared to non-treated infected mice. In conclusion, anandamide stimulated eryptosis of infected erythrocytes thus counteracting parasitaemia and a lethal course of the disease.

© 2010 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: June 15, 2010
Published online: August 24, 2010
Issue release date: August 2010

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: http://www.karger.com/CPB


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.